Biologic agents that revolutionized the treatment of patients with rheumatoid arthritis (RA) are now being reformulated as biosimilar agents. However, many questions remain regarding biosimilars: "What are they?", "Are they truly interchangeable with their reference biologics?", and "What are the clinical and financial implications of biosimilars in the treatment of patients with RA?" This archived symposium activity will provide participants with the opportunity to identify key differences between biosimilars and their reference biologics, review policy guidelines for biosimilars including naming and considerations for interchangeability, and assess data on the efficacy, safety, and clinical implications of biosimilars as part of RA patient management.
Improve your rheumatology knowledge by taking one of Elsevier's complimentary continuing medical education courses.
Evolving Treatment Paradigms for Rheumatoid Arthritis: Translating Comprehensive Patient Evaluations Into Personalized TherapyFormat: Webcast Series
Welcome to this RA CME Snapshot™ video series. Each 15-minute module offers focused, clinically actionable education for rheumatologists and other clinicians who manage patients with RA. For a comprehensive curriculum on current evidence-based guidelines and newly published data on the use of targeted inhibitors of interleukin (IL)-6 or Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathways, clinicians can complete all 6 video modules for a total of 1.5 AMA PRA Category 1 Credits™ or 1.5 hours of nursing contact hours.
Looking Beneath the Surface in Atopic Dermatitis: Targeting Immune Dysregulation and Delivering Comprehensive CareFormat: Webcast
This Interactive Exchange™ program will open with a brief 3D-animated video focused on the pathophysiologic underpinnings of atopic dermatitis. Expert faculty will then discuss best practices for comprehensive patient evaluations and the clinical profiles of systemic treatment options for patients with moderate-to-severe disease. With an overall goal of improving patient outcomes, this educational session has been designed to allow internationally recognized experts to translate the latest published evidence into actionable recommendations for individualized patient care.
Rheumatoid arthritis (RA) remains a clinically-challenging autoimmune disorder for rheumatologists to manage. Effective patient care is critical: an estimated sixty percent of people with inadequately-treated RA are unable to work 10 years following onset of the disease. The American College of Rheumatology (ACR) has endorsed the use of several quality improvement measures in RA management, including recommended screening, disease activity assessment, and treatment guidelines. However, clinical care of patients with respect to guideline recommendations continue to be suboptimal.
The Global Learning Center provides you with free access to the latest peer-reviewed clinical information relating to the treatment of psoriatic arthritis. The Psoriatic Arthritis Global Learning Center is a freely accessible platform that aims to increase clinical knowledge by providing continuing medical educational activities, research articles and resources for healthcare providers who treat patients with psoriatic arthritis.
The Global Learning Center provides you with free access to the latest peer-reviewed clinical information related to the treatment of patients with rheumatoid arthritis (RA). The RA Global Learning Center is a freely accessible platform that aims to increase clinical knowledge by providing continuing medical educational (CME) activities, research articles, and other resources to healthcare providers who treat patients with RA.